Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.49 USD
Change Today -0.24 / -3.10%
Volume 1.5M
INO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals DNA Vaccine Protects 100% against Deadly MERS Virus in Non-Human Primates

Inovio Pharmaceuticals announced its DNA vaccine targeting the virulent Middle East Respiratory Syndrome (MERS) induced 100% protection from a live virus challenge in a preclinical study. This medical advancement is notable because there is no vaccine or effective treatment for the MERS virus, which is clearly able to transmit from human to human. In preclinical studies, Inovio and its collaborators evaluated its synthetic DNA-based MERS vaccine in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. The data from camels is an important finding because camels represent not only a host reservoir of the disease but act as a mode of transmission to humans. In monkeys, all vaccinated animals in the study were protected from symptoms of MERS disease when challenged with a live MERS virus. Inovio has reported on the preventive power of its synthetic DNA-based vaccines in a variety of infectious diseases including HIV, influenza, hepatitis B, Ebola and dengue. Results from Inovio's MERS vaccine development efforts appear in the peer-reviewed journal Science Translational Medicine in an article entitled, "A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East Respiratory Syndrome Coronavirus in non-human primates." Inovio's collaborators for this study include researchers from the University of Pennsylvania, Public Health Agency of Canada, NIH, University of Washington, and University of South Florida.

Inovio Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Inovio Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $5,286,678 compared to $3,801,662 a year ago. Loss from operations was $15,120,093 compared to $10,152,946 a year ago. Net loss was $6,162,389 compared to $10,717,717 a year ago. Net loss attributable to the company was $6,248,250 compared to $10,711,274 a year ago. Net loss per diluted common share attributable to the stockholders of the company was $0.09 compared to $0.19 a year ago. For the six months, the company reported total revenues of $10,453,315 compared to $6,159,305 a year ago. Loss from operations was $23,487,704 compared to $20,153,001 a year ago. Net loss was $16,745,260 compared to $21,548,585 a year ago. Net loss attributable to the company was $16,830,029 compared to $21,532,734 a year ago. Net loss per diluted common share attributable to the stockholders of the company was $0.27 compared to $0.38 a year ago.

Inovio Pharmaceuticals Enters into Strategic Cancer Vaccine Collaboration and License Agreement with Medimmune

Inovio Pharmaceuticals announced that it has entered into a license agreement and collaboration with MedImmune. Under the agreement, MedImmune will acquire exclusive rights to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for more than 70% of cervical pre-cancers and cancers. MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. Emerging evidence suggests that the benefits from immuno-oncology molecules, such as those in MedImmune's portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumor-specific T-cells. Under the terms of the agreement, MedImmune will make an upfront payment of $27.5 million to Inovio as well as potential future payments upon reaching development and commercial milestones totaling up to $700 million. MedImmune will fund all development costs. Inovio is entitled to receive up to double-digit tiered royalties on INO-3112 product sales. Within the broader collaboration, MedImmune and Inovio will develop up to two additional DNA-based cancer vaccine products not included in Inovio's current product pipeline, which MedImmune will have the exclusive rights to develop and commercialize. Inovio will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net sales for these additional cancer vaccine products. The agreement builds on the existing partnership between Inovio and MedImmune on two research and development collaborations in the infectious disease area. Both efforts are funded by the Defense Advanced Research Projects Agency (DARPA) and support R&D focused on Ebola, influenza, and bacterial infections.

Inovio Eyes Acquisitions

Inovio Pharmaceuticals, Inc. (NasdaqGS:INO) is looking for acquisitions. The company has filed a Shelf Registration in the amount of $250 million and will use the proceeds for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses and potential acquisitions of companies and technologies that complement their business.

Inovio Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Inovio Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $7.49 USD -0.24

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $14.80 USD -0.31
Dynavax Technologies Corp $28.36 USD -1.40
Genocea Biosciences Inc $11.63 USD -0.58
Peregrine Pharmaceuticals Inc $1.15 USD 0.00
Vical Inc $0.59 USD +0.0002
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.5x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.